Hikma Pharmaceuticals (HIK) Competitors GBX 1,953 +18.00 (+0.93%) (As of 12/20/2024 12:01 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability HIK vs. HCM, INDV, AMYT, AGY, APH, BXP, ANCR, DNL, EAH, and STXShould you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Diurnal Group (DNL), ECO Animal Health Group (EAH), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry. Hikma Pharmaceuticals vs. HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Beximco Pharmaceuticals Animalcare Group Diurnal Group ECO Animal Health Group Shield Therapeutics Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Is HIK or HCM more profitable? Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.88% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets Hikma Pharmaceuticals9.45% 12.88% 9.40% HUTCHMED -6.87%-5.44%-5.90% Do analysts recommend HIK or HCM? Hikma Pharmaceuticals currently has a consensus price target of GBX 2,383.33, suggesting a potential upside of 22.03%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in HIK or HCM? 42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 39.0% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation & earnings, HIK or HCM? Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHikma Pharmaceuticals£3.02B1.43£285M£0.653,004.62HUTCHMED£610.81M3.32-£41.97M-£0.04-5,925.00 Does the media favor HIK or HCM? In the previous week, Hikma Pharmaceuticals and Hikma Pharmaceuticals both had 1 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.19 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor HIK or HCM? Hikma Pharmaceuticals received 604 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.55% of users gave Hikma Pharmaceuticals an outperform vote. CompanyUnderperformOutperformHikma PharmaceuticalsOutperform Votes80070.55% Underperform Votes33429.45% HUTCHMEDOutperform Votes19678.40% Underperform Votes5421.60% Which has more volatility and risk, HIK or HCM? Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. SummaryHikma Pharmaceuticals beats HUTCHMED on 13 of the 17 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIK vs. The Competition Export to ExcelMetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£4.33B£1.15B£5.13B£1.84BDividend Yield3.25%3.04%5.08%10.58%P/E Ratio3,004.62131.2389.581,771.92Price / Sales1.431,962.971,116.12375,802.49Price / Cash8.3410.1142.8227.86Price / Book1.893.064.772.89Net Income£285M£152.21M£120.15M£155.43M7 Day Performance0.98%-0.48%-1.92%-1.91%1 Month Performance4.33%-1.32%11.47%17.44%1 Year Performance9.17%98.66%30.54%28.79% Hikma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIKHikma Pharmaceuticals1.5311 of 5 starsGBX 1,953+0.9%GBX 2,383.33+22.0%+8.3%£4.33B£3.02B3,004.629,100News CoverageHCMHUTCHMEDN/AGBX 239-3.2%N/A-12.9%£2.04B£610.81M-6,150.001,760INDVIndivior2.503 of 5 starsGBX 950+4.6%GBX 1,500+57.9%-22.5%£1.22B£1.15B-1,135.001,000Analyst ForecastAMYTAmryt PharmaN/AGBX 143-11.7%N/A+0.0%£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 6.40+3.2%N/A+190.9%£305.28M£53.26M-103.33612Gap DownAPHAlliance Pharma3.3023 of 5 starsGBX 48.40+0.4%GBX 60+24.0%+15.2%£261.64M£183.15M-803.3391,000News CoveragePositive NewsBXPBeximco PharmaceuticalsN/AGBX 37.70+7.7%N/A-14.6%£168.18M£43.08B471.255,500News CoverageGap UpANCRAnimalcare GroupN/AGBX 240-0.6%N/A+35.9%£144.89M£76.10M3,023.13220DNLDiurnal GroupN/AGBX 27.30flatN/A+0.0%£46.33M£4.68M-3.2133EAHECO Animal Health GroupN/AGBX 68.14-2.7%N/A-34.6%£46.16M£89.42M3,450.00234Gap DownSTXShield TherapeuticsN/AGBX 2.65-1.7%N/A-58.3%£20.75M£21.47M-68.0040,000 Related Companies and Tools Related Companies HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Beximco Pharmaceuticals Alternatives Animalcare Group Alternatives Diurnal Group Alternatives ECO Animal Health Group Alternatives Shield Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HIK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.